» Articles » PMID: 21789134

Castration-resistant Prostate Cancer: New Science and Therapeutic Prospects

Overview
Specialty Oncology
Date 2011 Jul 27
PMID 21789134
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

There is a growing number of new therapies targeting different pathways that will revolutionize patient management strategies in castration-resistant prostate cancer (CRPC) patients. Today there are more clinical trial options for CRPC treatment than ever before, and there are many promising agents in late-stage clinical testing. The hypothesis that CRPC frequently remains driven by a ligand-activated androgen receptor (AR) and that CRPC tissues exhibit substantial residual androgen levels despite gonadotropin-releasing hormone therapy, has led to the evaluation of new oral compounds such as abiraterone and MDV 3100. Their results, coupled with promising recent findings in immunotherapy (eg sipuleucel-T) and with agents targeting angiogenesis (while awaiting the final results of the CALGB trial 90401) will most probably impact the management of patients with CRPC in the near future. Other new promising agents need further development. With our increased understanding of the biology of this disease, further trial design should incorporate improved patient selection so that patient populations are those who may be most likely to benefit from treatment.

Citing Articles

Chronic IL-1-Exposed LNCaP Cells Evolve High Basal p62-KEAP1 Complex Accumulation and NRF2/KEAP1-Dependent and -Independent Hypersensitive Nutrient Deprivation Response.

Dahl-Wilkie H, Gomez J, Kelley A, Manjit K, Mansoor B, Kanumuri P Cells. 2025; 14(3).

PMID: 39936983 PMC: 11816438. DOI: 10.3390/cells14030192.


Lower baseline testosterone level is related to earlier development of castration resistance in metastatic prostate cancer: a multi-center cohort study.

Wong H, Chiu P, Puche-Sanz I, Xue Z, Chen D, Gomez-Gomez E Front Oncol. 2024; 14:1321522.

PMID: 38444678 PMC: 10913891. DOI: 10.3389/fonc.2024.1321522.


Emerging role of transforming growth factor-β-regulated long non-coding RNAs in prostate cancer pathogenesis.

Shree B, Das K, Sharma V Cancer Pathog Ther. 2024; 1(3):195-204.

PMID: 38327834 PMC: 10846338. DOI: 10.1016/j.cpt.2022.12.003.


Systematic review of antitumour efficacy and mechanism of metformin activity in prostate cancer models.

Wang N, Jue T, Holst J, Gunter J BJUI Compass. 2022; 4(1):44-58.

PMID: 36569495 PMC: 9766874. DOI: 10.1002/bco2.187.


BK002 Induces miR-192-5p-Mediated Apoptosis in Castration-Resistant Prostate Cancer Cells Modulation of PI3K/CHOP.

Park M, Park H, Rahman M, Kim J, Park S, Cho Y Front Oncol. 2022; 12:791365.

PMID: 35321434 PMC: 8936126. DOI: 10.3389/fonc.2022.791365.


References
1.
Lin B, White J, Lu W, Xie T, Utleg A, Yan X . Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease. Cancer Res. 2005; 65(8):3081-91. DOI: 10.1158/0008-5472.CAN-04-3218. View

2.
Majumder P, Sellers W . Akt-regulated pathways in prostate cancer. Oncogene. 2005; 24(50):7465-74. DOI: 10.1038/sj.onc.1209096. View

3.
Rosenberg J, Weinberg V, Kelly W, Michaelson D, Hussain M, Wilding G . Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 2007; 110(3):556-63. DOI: 10.1002/cncr.22811. View

4.
Koutsilieris M, Mitsiades C, Bogdanos J, Dimopoulos T, Karamanolakis D, Milathianakis C . Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Clin Cancer Res. 2004; 10(13):4398-405. DOI: 10.1158/1078-0432.CCR-04-0077. View

5.
Miyake H, Chi K, Gleave M . Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res. 2000; 6(5):1655-63. View